

INVESTOR CONFERENCE CALL INVITE

Q4 & FY 2016-17

Syngene's Q4 FY17 and full year FY17 Results Conference Call

At 03:30 pm IST on 28th April, 2017

The management team of Syngene International Limited ("Syngene") will organize a **conference call for Analysts and Investors on Friday, 28th April at 03:30 pm IST** following the announcement of financial results for the quarter and year ended March 31, 2017.

The call will be initiated with a brief management discussion on the Q4 FY17 and Full Year FY17 performance followed by an interactive Question & Answer session. Mr. Jonathan Hunt, Chief Executive Officer and other members of the senior management team will represent Syngene on the conference call.

Details of the conference call are as under:

Date:	Friday, 28 th April 2017
Time:	03:30 pm to 04:30 pm IST
Dial-in Numbers:	
Primary Number	+91 22 3960 0674
Local Access Number	3940 3977: Available in Ahmedabad, Bangalore, Chandigarh, Chennai, Gurgaon (NCR), Hyderabad, Kochi/Cochin, Kolkata, Lucknow, Pune (Accessible from all carriers.)
International Toll Free Numbers	<ul style="list-style-type: none">• USA - 18667462133• UK - 08081011573• Singapore - 8001012045• Hong Kong - 800964448

INVESTOR CONFERENCE CALL INVITE

Q4 & FY 2016-17

Pre-registration Facility	<p>Step 1: Pre-register here. You will receive a passcode and a pin for the call on the registered email address</p> <p>Step 2: Dial into the call on the Conference Call date, enter the passcode & pin as prompted. You will be directly connected to the call</p>
Replay Facility	<p>Dial in numbers: +91 22 3065 2322</p> <p>Playback ID: 96431</p> <p>The replay facility will begin after the conference call ends.</p> <p>Replay available till 5th May 2017</p>
Conference Call Transcript	<p>Will be available within 7 working days of the call on the corporate website: www.syngeneintl.com</p>

About Syngene

Syngene International Limited, **(BSE code: 539268, NSE Id: SYNGENE, ISIN Id: INE398R01022)** is one of Asia's largest Contract Research Organizations. It provides discovery and developmental services for new molecular entities across multiple platforms including Small Molecules, Large Molecules, Antibody-Drug Conjugates and Oligonucleotides. These services are aimed towards bringing novel molecules to the market by supporting the R&D efforts of organizations across diverse sectors like pharma, biotechnology, nutrition and animal health. In FY2016, Syngene serviced 250+ clients including 8 of the top 10 global pharma companies (by 2015 revenue). For more details, visit: www.syngeneintl.com

For further information, please contact:

Chanderlekha Nayar

Syngene International

☎: +91 80 6775 8821 | Fax: +91 80 2852 3423

✉: Chanderlekha.Nayar@syngeneintl.com

Disclaimer: Certain of the statements that may be made or discussed at the conference call may be forward-looking statements and/or based on management's current expectations and beliefs concerning future developments and their potential effects upon Syngene and its associates. There can be no assurance that future developments affecting Syngene and its associates will be those anticipated by management. These forward-looking statements are not a guarantee of future performance and involve risks and uncertainties and there are important factors that could cause actual results to differ, possibly materially, from expectations reflected in such forward-looking statements. Syngene does not intend, and is under no obligation, to update any particular forward-looking statement made at the conference call.